The Effectiveness of PRP Therapy in Women after Urinary Incontinence Surgery

Female sexual dysfunction (FSD) and stress urinary incontinence (SUI) are prevalent conditions that severely affect the quality of life of women, often with limited non-surgical treatment options. Platelet-rich plasma (PRP) therapy, known for its regenerative properties, is emerging as a potential treatment for these conditions. Despite promising preclinical results, there is a lack of consensus on the efficacy, optimal dosing, and administration sites for PRP injections in treating FSD and SUI. This systematic review evaluates the efficacy and safety of PRP injections for FSD and SUI. A comprehensive search of PubMed, Embase, and the Cochrane Library was conducted, including clinical studies on humans. Data were assessed for bias using RoB-2 for randomized controlled trials (RCTs) and the Newcastle-Ottawa Scale (NOS) for observational studies. The review included 12 studies involving 327 women, with 172 treated for FSD and 155 for SUI. PRP injections significantly improved clinical scores such as the Female Sexual Function Index (FSFI), Vaginal Health Index (VHI), International Consultation on Incontinence Questionnaire—Short Form (ICIQ-SF), and Urogenital Distress Inventory (UDI-6). The studies indicated PRP's efficacy with minimal adverse events.PRP therapy demonstrated significant improvements in FSD and SUI symptoms, though results were constrained by study heterogeneity and risk of bias. Notable improvements were observed in the FSFI and VHI for FSD, and ICIQ-SF and UDI-6 scores for SUI. PRP injections present a promising, minimally invasive treatment for FSD and SUI. However, high-quality RCTs are needed to establish standardized protocols and confirm long-term efficacy and safety. This study underscores the potential of PRP therapy while highlighting the necessity for further research to solidify its clinical utility.